Eye Drop Composition Novel Axitinib Molecular Association
Summary
USPTO published patent application US20260108505A1 for an eye drop composition comprising a novel molecular association of axitinib physically bound with solubilizers, stabilizers, and additives including buffers, osmotic pressure regulators, and pH adjusters. The application was filed by SCAI Therapeutics Co., Ltd. on March 4, 2025. CPC classifications include A61K 31/4439, A61K 9/08, and A61P 27/02, indicating a pharmaceutical composition for ophthalmic use.
“A composition containing a molecular association in which axitinib is physically bound and a method for preparing the composition are disclosed.”
About this source
GovPing monitors USPTO Patent Applications - Therapeutics (A61P) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 229 changes logged to date.
What changed
USPTO published patent application US20260108505A1 disclosing a novel eye drop composition in which axitinib is physically bound within a molecular association structure, combined with solubilizers, stabilizers, and optional additives such as buffers, osmotic pressure regulators, and pH adjusters. The filing covers both the composition and its method of preparation.
Pharmaceutical companies developing ophthalmic formulations or axitinib-based therapeutics should monitor this application for potential freedom-to-operate implications. Competitors with existing or planned eye care products should evaluate whether the disclosed molecular association approach represents a novel non-obvious formulation technique that could affect their IP strategy.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
EYE DROP COMPOSITION COMPRISING NOVEL MOLECULAR ASSOCIATION OF AXITINIB AND METHOD FOR PREPARING THE SAME
Application US20260108505A1 Kind: A1 Apr 23, 2026
Assignee
SCAI THERAPEUTICS CO., LTD.
Inventors
Chul Hwan KIM, Kyoung Hee KIM, Sung-Woo HWANG
Abstract
A composition containing a molecular association in which axitinib is physically bound and a method for preparing the composition are disclosed. The composition contains a molecular association in which axitinib is physically bound, a solubilizer, a stabilizer, and an additive. The additive may include any one or more selected from a buffer, an osmotic pressure regulator, and a pH adjuster.
CPC Classifications
A61K 31/4439 A61K 9/08 A61P 27/02
Filing Date
2025-03-04
Application No.
19147858
Mentioned entities
Related changes
Get daily alerts for USPTO Patent Applications - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.